Resource Summary Report

Generated by dkNET on Sep 9, 2026

SU-DHL-4

RRID:CVCL_0539
Type: Cell Line

Proper Citation

RRID:CVCL_0539

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0539

Proper Citation: RRID:CVCL_0539

Description: Cell line SU-DHL-4 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Diffuse large B-cell lymphoma germinal center B-cell type

Defining Citation: PMID:83902, PMID:177185, PMID:214220, PMID:371794, PMID:2875799, PMID:2985879, PMID:3159941, PMID:3874327, PMID:3881165, PMID:8547074, PMID:8957066, PMID:9738977, PMID:9787181, PMID:10739008, PMID:11226526, PMID:12169673, PMID:17363600, PMID:18357372, PMID:19278952, PMID:20054396, PMID:20628145, PMID:20889926, PMID:22460905, PMID:23292937, PMID:25355872, PMID:25485619, PMID:25877200, PMID:25894527, PMID:26589293, PMID:26727417, PMID:27397505, PMID:28196595, PMID:28356514, PMID:29416618, PMID:29666304, PMID:30165192, PMID:30285677, PMID:30629668, PMID:30894373, PMID:31068700, PMID:31160637, PMID:31978347, PMID:35839778

Comments: Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: LL-100 blood cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SU-DHL-4

Synonyms: SUDHL4, Sudhl4, SUDHL-4, Sudhl-4, SuDHL 4, SUD-4, SUD4, SU4, Stanford University-Diffuse Histiocytic Lymphoma-4, DHL-4, DHL4

Cross References: BTO:BTO_0006462, CLO:CLO_0037061, EFO:EFO_0006492, MCCL:MCC:0000440, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, ATCC:CRL-2957, BioGRID_ORCS_Cell_line:742, BioSample:SAMN03473232, BioSample:SAMN10988472, cancercelllines:CVCL_0539, CCRID:3101HUMSCSP5048, Cell_Model_Passport:SIDM00405, ChEMBL-Cells:CHEMBL3308053, ChEMBL-Targets:CHEMBL613711, CLS:305106, Cosmic:850203, Cosmic:932763, Cosmic:999780, Cosmic:1067443, Cosmic:1079254, Cosmic:1517656, Cosmic:1541909, Cosmic:1636687, Cosmic:1714160, Cosmic:1945192, Cosmic:2276338, Cosmic:2361375, Cosmic:2437313, Cosmic-CLP:1331035, DepMap:ACH-000365, DSMZ:ACC-495, DSMZCellDive:ACC-495, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, ENCODE:ENCBS265MKB, ENCODE:ENCBS980NLV, GDSC:1331035, GEO:GSM274842, GEO:GSM380145, GEO:GSM499735, GEO:GSM552463, GEO:GSM562826, GEO:GSM887653, GEO:GSM888745, GEO:GSM1035322, GEO:GSM1374906, GEO:GSM1670485, IARC_TP53:25031, IARC_TP53:28236, ICLC:HTL10002, LiGeA:CCLE_386, LINCS_LDP:LCL-1136, Lonza:270, PharmacoDB:SUDHL4_1502_2019, PRIDE:PXD000589, PRIDE:PXD030304, Progenetix:CVCL_0539, PubChem_Cell_line:CVCL_0539, Ubigene:YC-C082, Wikidata:Q54970717

ID: CVCL_0539

Record Creation Time: 20220427T221612+0000

Record Last Update: 20260905T182514+0000

Ratings and Alerts

No rating or validation information has been found for SU-DHL-4.

Warning: Discontinued: ICLC; HTL10002
Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: LL-100 blood cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 60 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

Demel UM, et al. (2026) Aberrant SUMOylation Restricts the Targetable Cancer Immunopeptidome. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(17), e11449.

Kunzmann GB, et al. (2026) Dynamic UFMylation governs cellular fitness by coordinating multi-organelle proteostasis. bioRxiv : the preprint server for biology.

Sun W, et al. (2026) Reconstruction of T cell infiltration in an osteosarcoma PDX-organoid interactive biobank for personalized immunotherapy. Cell reports. Medicine, 7(3), 102644.

Enssle JC, et al. (2026) Pathogenesis of diffuse large B cell lymphoma proteogenotypes. Cancer cell, 44(7), 1437.

Calaud C, et al. (2026) Enhanced efficacy of a specific HDAC3 inhibitor in combination with 5-azacitidine against diffuse large B-cell lymphoma. Blood neoplasia, 3(2), 100214.

Rossi A, et al. (2025) Downregulation of rRNA synthesis by BCL-2 induces chemoresistance in diffuse large B cell lymphoma. iScience, 28(5), 112333.

Lüönd F, et al. (2025) DLBCL Cells Emerge after CD19 CAR T Cells with Cross-Antigen Resistance and a Gene Signature Predictive of Clinical CAR T-cell Response. Blood cancer discovery, 6(6), 580.

Shi X, et al. (2025) NFS1, together with FXN, protects cells from ferroptosis and DNA damage in diffuse large B-cell lymphoma. Redox biology, 87, 103878.

Peled A, et al. (2025) BKT300: A Novel Anti-Leukemic Small Molecule Targeting the Protein Regulator of Cytokinesis 1 (PRC1) Pathway. Research square.

Abdelhamed S, et al. (2025) PF-08046032: A Novel, Investigational CD25-Directed Antibody-Drug Conjugate Optimized for Selective Depletion of Regulatory T Cells in Advanced Malignant Tumors. Molecular cancer therapeutics, 24(7), 963.

Mani R, et al. (2025) TP53 upregulation via aurora kinase inhibition overcomes primary failure to venetoclax in BCL2-rearranged lymphomas. iScience, 28(6), 112584.

Porazzi P, et al. (2025) EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models. Cancer cell, 43(3), 537.

Chen Z, et al. (2025) YTHDF2 promotes ATP synthesis and immune evasion in B cell malignancies. Cell, 188(2), 331.

Reversat A, et al. (2025) Mass Cytometry-Based Approach for the Investigation of Stimulator of Interferon Genes Pathway. European journal of immunology, 55(12), e70101.

McCrury M, et al. (2024) Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma. Molecular cancer therapeutics, 23(3), 316.

Choi J, et al. (2024) Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas. Cancer cell, 42(5), 833.

Layden HM, et al. (2024) Mutant FOXO1 controls an oncogenic network via enhancer accessibility. Cell genomics, 4(4), 100537.

Rane G, et al. (2024) ZBTB48 is a priming factor regulating B-cell-specific CIITA expression. The EMBO journal, 43(24), 6236.

Li J, et al. (2024) Loss of CREBBP and KMT2D cooperate to accelerate lymphomagenesis and shape the lymphoma immune microenvironment. Nature communications, 15(1), 2879.

He MY, et al. (2024) GNAS knockout potentiates HDAC3 inhibition through viral mimicry-related interferon responses in lymphoma. Leukemia, 38(10), 2210.